Primary efficacy analysis (mITT population) included 194 subjects: 400 mg QD (48), 800 mg QD (53), 400 mg BID (46), and placebo (47).
Least squares mean percent change from baseline was statistically significant compared with placebo for the 800 mg QD group (-48 .2% vs -25.0%; P=.001) and the 400 mg BID group (-50 .7% vs -25.0%; P<.001); the difference between 400 mg QD and placebo did not reach statistical significance (-38 .1% vs -25.0%; P=.066) (Table 1) ( Figure 1 ). Diarrhea was the most common TEAE, reported in 22.4%, 40.0%, 39.6%, and 14.6% of subjects in the XP-23829 400 mg QD, 800 mg QD, 400 mg BID, and placebo groups, respectively. Most cases of diarrhea were mild to moderate in severity (Table 2) . Nausea and abdominal pain were reported in more than 10% of the overall XP-23829 population ( Table 2) .
Flushing was reported in 5.9% of XP-23829 subjects and 6.3% of placebo subjects (Table 2) .
No subject demonstrated grade 3 or 4 lymphopenia (Table 2) .
No new or unexpected adverse events related to XP-23829 were reported compared to what is known for the FAE class (Table 2) .
XP-23829, a novel fumaric acid ester, is efficacious in reducing psoriatic lesions:
Results from a phase 2 randomized controlled study 
Conclusions
In this study XP-23829 in 400 mg BID and 800 mg QD doses demonstrated significant efficacy over 12-week of treatment and efficacy did not appear to have plateaued at the end of the study.
Efficacy and safety is being further assessed in a 24-week phase 2 study. 200 subjects randomized in a 1:1:1:1 ratio into 4 arms: 400 mg QD, 400 mg BID, 800 mg QD, Placebo.
Methods
A 3-week titration phase was followed by 9 weeks of treatment.
The primary endpoint was the percentage change in PASI score from baseline to the end of week 12. 
Results

Introduction
Dimethyl Fumarate (DMF) is a fumaric acid ester (FAE) approved in Germany for the treatment of moderate to severe chronic plaque psoriasis. Monomethyl fumarate (MMF) is the active moiety of DMF.
XP-23839 is an extended release FAE that is being developed for the treatment of moderate to severe plaque psoriasis.
Here, we examine a phase 2 study to evaluate the safety and efficacy of 3 doses and 2 dosing regimens at 12 weeks. 
